Navigation Links
OxThera Strengthens Patent Portfolio for Orphan Disease - Primary Hyperoxaluria

STOCKHOLM, June 4, 2013 /PRNewswire/ --

OxThera AB has been granted three Japanese patents during 2012 and 2013. The patents will secure the pharmaceutical composition and the method for treating and preventing oxalate-related disease with micro-organisms and enzymes and will further strengthen the Company's patent estate for this unmet medical need.

"We are continuously working to further strengthen the world-wide rights for our lead product Oxabact®" for treatment of Primary Hyperoxaluria, an orphan disease," says Elisabeth Lindner , CEO of OxThera. "The Japanese rights are important additions to our already granted patents in the EU and the US. Japan is an important market for hyperoxaluria" Elisabeth Lindner continues.

OxThera holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in seven patent families with approximately eighty applications filed. The new granted Japanese patents have numbers 4996780, 5047190 and 5203217.

Oxabact® is an oral product composed of highly concentrated freeze-dried live bacteria (Oxalobacter formigenes), administered in capsules. The drug is designed for delivery in the lower part of the small intestine, where enteric elimination of endogenous oxalate is initiated. OxThera is currently pursuing a complete Oxabact® clinical development plan in the EU and in the US for the treatment of patients suffering from Primary Hyperoxaluria.

About Primary Hyperoxaluria

Primary Hyperoxaluria is a rare inborn autosomal genetic disorder leading to markedly elevated levels of endogenous oxalate in plasma and urine. High levels of urinary oxalate cause kidney damage, including kidney stone formation and/or calcification of the kidney. If left untreated, the disease can cause kidney failure and premature death. There is a high medical need for effective treatments of Primary Hyperoxaluria. Currently, the only available cure is a combined liver and kidney transplantation.

Oxabact® holds orphan drug designations in the EU and the US for the treatment of Primary Hyperoxaluria.

About OxThera

OxThera holds worldwide rights for compositions and methods of use for treatment of hyperoxaluria. OxThera currently has two products in its pipeline: Oxabact® for the treatment of Primary Hyperoxaluria, and Oxazyme®, an oxalate decarboxylase, for the prevention of oxalate malabsorption and recurring kidney stones in Secondary Hyperoxaluria. OxThera operates through the head office in Stockholm, Sweden, and its subsidiary OxThera Inc. in Alachua, Florida, USA.

For further information, please contact Elisabeth Lindner , CEO of OxThera AB, Phone +46-8-660-02-23

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CareFusion Strengthens U.K. Presence With Acquisition of Medical Products Distributor
2. Tris Pharma Expands Manufacturing Capacity and Strengthens Supply Chain to Support New and Pending Approvals
3. RxAlly Strengthens Leadership Team With New Chief Information Officer Mike Groh
4. PAREXEL Strengthens Outcomes Research Capabilities To Help Biopharma Meet Commercialization Goals
5. Actinium Pharmaceuticals Strengthens Management Team
6. Pharmalink AB Strengthens Senior Management Team
7. Jardogs Strengthens Leadership Team with the Addition of Two Seasoned Healthcare Executives
8. inVentiv Health Strengthens Clinical Leadership Team
9. Alliqua Strengthens and Realigns Executive Team
10. Neuland Labs Strengthens Commitment to Japanese Market With New Manufacturing Collaboration With Mitsubishi Healthcare Unit API Corporation
11. TransCelerate BioPharma Inc. Grows, Strengthens Novel Effort to Accelerate Drug Development
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the ... affiliation with Tennessee Counseling Association. This new relationship allows TherapySites to ... Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Viejo, California (PRWEB) , ... June 26, 2016 , ... ... Final Cut Pro X. , "Film editors can give their videos a whole new ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
Breaking Medicine News(10 mins):